Rethinking Old Drugs for Parkinson’s

Finding new medicines for Parkinson’s Disease is a slow and costly process. Most drugs available today help manage symptoms but do not stop the disease from progressing. This has led scientists to look again at medicines that already exist to see if some could be repurposed for Parkinson’s. Drug repurposing means taking a medicine that was designed for one illness and testing whether it can also help in another. Because these drugs have already passed safety checks, research can move faster and cost less. The idea is simple but powerful — instead of waiting years for a new molecule to be approved, we might find that something sitting on a pharmacy shelf already has benefits for people with Parkinson’s. The recent study on this topic argues that Parkinson’s is too complex to fix with one single treatment. It affects energy production in cells, causes inflammation in the brain, and leads to a build-up of damaged proteins. So, the authors suggest a multidimensional approach — meaning several pathways should be targeted at once. They believe that combining repurposed drugs with different effects could give better long-term results than focusing on just one mechanism. One of the most talked-about examples is a group of diabetes medicines called GLP-1 receptor agonists. These drugs, such as exenatide and lixisenatide, were designed to control blood sugar levels. But scientists discovered that they may also protect brain cells and reduce inflammation. Early trials looked promising, and many people hoped they might slow Parkinson’s progression. However, the largest trial with exenatide found no real difference between treated and untreated patients. Still, some smaller studies with similar drugs are continuing, as researchers think different doses or newer versions might still hold potential. Another strong candidate is ambroxol, a simple cough medicine that has been used safely for decades. Ambroxol affects a pathway linked to a gene called GBA, which is known to raise the risk of Parkinson’s. In lab tests, it helped cells clear out waste proteins — the same proteins that build up in the brains of people with Parkinson’s. Early clinical studies suggest that ambroxol can reach the brain and might increase levels of an important enzyme that keeps cells healthy. Larger trials are now underway to see if these effects actually translate into slower disease progression. Some cancer drugs have also been tested. Medicines such as nilotinib and imatinib were developed to block an enzyme called c-Abl, which can interfere with the brain’s ability to recycle damaged proteins. In theory, blocking this enzyme might help protect nerve cells. Small early studies created excitement, but later trials showed mixed results, with limited benefits and potential side effects. This line of research continues, though more cautiously. Other repurposing ideas include anti-inflammatory drugs to calm overactive immune responses in the brain, antioxidants to fight oxidative stress, and compounds that boost mitochondria — the tiny power plants inside cells that produce energy. Each of these targets addresses part of the wider puzzle of how Parkinson’s damages the brain. What makes this approach appealing is that it builds on what we already know. Instead of starting from zero, scientists can use approved medicines, shorten the research timeline, and reduce the cost of getting them into trials. But it also comes with limits. Just because a drug works for one disease does not mean it will work for Parkinson’s. And even when it looks promising in the lab, it still needs to pass the same strict tests as any new treatment before doctors can prescribe it. The message from the study is hopeful but realistic. Drug repurposing is not a quick fix, but it offers a smart and practical way to move closer to a real disease-modifying therapy for Parkinson’s. By combining insight from genetics, cell biology, and clinical trials, researchers are building a stronger foundation for progress. For now, people with Parkinson’s can take heart that the scientific community is exploring every possible angle — even the ones hiding in plain sight on the shelves of existing medicine cabinets.